The Therapeutic Potential of CBD In Parkinson's Disease: Advances And Challenges
DOI:
https://doi.org/10.36557/2674-8169.2025v7n12p1382-1407Keywords:
Cannabidiol, Parkinson’s Disease, NeuroprotectionAbstract
Cannabidiol (CBD) is a compound obtained from the plant Cannabis sativa that has stood out in the scientific literature due to its anxiolytic, antioxidant, anti-inflammatory, and neuroprotective properties. Nowadays, its therapeutic potential has been investigated in various neurological conditions, including Parkinson’s Disease (PD), a chronic neurodegenerative disorder that progressively impairs both motor and non-motor functions. The aim of this study was to examine the effects of CBD on PD, considering its therapeutic benefits and possible side effects. The methodology consisted of a literature review, selecting articles published mainly between 2014 and 2025, from the PubMed and SciELO databases. The studies suggest that CBD may contribute to the treatment of non-motor symptoms of PD, such as sleep disturbances, psychosis, and anxiety, generally presenting a good safety profile. However, its effects on motor symptoms remain inconclusive, and there are reports of significant drug interactions and adverse reactions. Regulatory barriers and the need for standardization in the administration of the compound were also highlighted. It is concluded that, although current data are promising, the efficacy of CBD in PD is not yet proven, and more robust, long-term clinical research is needed to validate its therapeutic use safely.
Downloads
References
AQUINO Y. C.; CABRAL L. M.; MIRANDA N. C.; NACCARATO M. C.; FALQUETTO B.; MOREIRA T. S.; TAKAKURA A. C. Respiratory disorders of Parkinson's disease. Journal of Neurophysiology, v. 27, n. 1, p. 1-15, 2022.
BALACHANDRAN P.; ELSOHLY M.; HILL K. P. Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review. Journal of General Internal Medicine, v. 36, p. 2074-2084, 2021.
BERGER M.; LI E.; RICE S.; DAVEY C. G.; RATHEESH A.; ADAMS S.; JACKSON H.; HETRICK S.; PARKER A.; SPELMAN T.; KEVIN R.; MCGREGOR I. S.; MCGORRY P.; AMMINGER G. P. Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial. The Journal Clinical Psychiatry, v. 83, n. 5, e14221, 2022.
BIANCHI M. L. E.; RIBOLDAZZI G.; MAURI M.; VERSINO M. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease. Neurological Sciences, v. 40, p. 275-279, 2019.
BOROWICZ-REUTT K.; CZERNIA J.; KRAWCZYK M. CBD in the Treatment of Epilepsy. Molecules, v. 29, n. 9, art. 1981, 2024.
CHAGAS, M. H. N.; ECKELI, A. L.; ZUARDI, A. W.; PENA-PEREIRA, M. A.; SOBREIRA-NETO, M. A.; SOBREIRA, E. T.; CAMILO, M. R.; BERGAMASCHI, M. M.; SCHENCK, C. H.; HALLAK, J. E. C.; TUMAS, V.; CRIPPA, J. A. S. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. Journal of Clinical Pharmacy and Therapeutics, v. 39, n. 5, p. 564–566, out. 2014a.
CHAGAS, M. H.; ZUARDI, A. W.; TUMAS, V.; PENA-PEREIRA, M. A.; SOBREIRA, E. T.; BERGAMASCHI, M. M.; DOS SANTOS, A. C.; TEIXEIRA, A. L.; HALLAK, J. E.; CRIPPA, J. A. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. Journal of Psychopharmacology, v. 28, n. 11, p. 1088-1098, 2014b.
CHURCH FC. Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease. Biomolecules, v. 11, n. 4, art. 612, 2021.
CONSROE, P.; SANDYK, R.; SNIDER, S. R. Open label evaluation of cannabidiol in dystonic movement disorders. International Journal of Neuroscience, v. 30, n. 4, p. 277–282, 1986.
COORAY R.; GUPTA V.; SUPHIOGLU C. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review. Molecular Neurobiology, v. 57, p. 4878-4890, 2020.
CRIPPA J. A. S.; HALLAK J. E. C.; ZUARDI A. W.; GUIMARÃES F. S.; TUMAS V.; DOS SANTOS R. G. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms? European Archives Psychiatry and Clinical Neuroscience, v. 269, p. 121-133, 2019.
CROCQ, M. A. History of cannabis and the endocannabinoid system. Dialogues in Clinical Neuroscience, v. 22, n. 3, p. 223–228, 2020.
DEVINSKY O.; CILIO M. R.; CROSS H.; FERNANDEZ-RUIZ J.; FRENCH J.; HILL C.; KATZ R.; DI MARZO V.; JUTRAS-ASWAD D.; NOTCUTT W. G.; MARTINEZ-ORGADO J.; ROBSON P. J.; ROHRBACK B. G.; THIELE E.; WHALLEY B.; FRIEDMAN D. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia Official Journal of the International League Against Epilepsy, v. 55, n. 6, p. 791-802, 2014.
DORIS J. M.; MILLAR S. A.; IDRIS I.; O'SULLIVAN S. E. Genetic polymorphisms of the endocannabinoid system in obesity and diabetes. Diabetes. Obesity and Metabolism, v. 21, p. 382-387, 2018.
DOS SANTOS R. G.; HALLAK, J. E. C.; CRIPPA, J. A. S. O uso do canabidiol (CBD) no tratamento da doença de Parkinson e suas comorbidades. Revista de Medicina (São Paulo), v. 98, n. 1, p. 70-75, 2019.NAS CITAÇÕES ESTAVA SOENTE SANTOS, 2019.
ELSAID S.; KLOIBER S.; FOLLA B. L. Chapter Two - Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Progress in Molecular Biology and Translational Science, v. 167, p. 25-75, 2019.
FENG Y.; CHEN F.; YIN T.; XIA Q.; LIU Y.; HUANG G.; ZHANG J.; OYEN R.; NI Y. Pharmacologic Effects of Cannabidiol on Acute Reperfused Myocardial Infarction in Rabbits: Evaluated With 3.0T Cardiac Magnetic Resonance Imaging and Histopathology. Journal of Cardiovascular Pharmacology, v. 66, n. 4, p 354-363, 2015.
FERNANDEZ-RUIZ J.; SAGREDO O.; PAZOS M. R.; GARCÍA C.; PERTWEE R.; MECHOULAM R.; MARTÍNEZ-ORGADO J. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? British Pharmacological Society, v. 75, n. 2, p. 323-333, 2013.
FERREIRA JUNIOR, N. C.; DOS-SANTOS-PEREIRA, M.; GUIMARÃES, F. S.; DEL BEL, E. Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson’s disease and l-DOPA-induced dyskinesia. Neurotoxicity Research, v. 37, n. 1, p. 12-29, 2019.
FLORES, L. E.; ZAMIN, L. L. Potencial neuroprotetor, antioxidante e anti-inflamatório do Canabidiol: relevância e perspectivas para o tratamento de doenças neurodegenerativas. Revista de Ciências Médicas e Biológicas, Salvador, v. 16, n. 2, p. 224–229, 2017.
GOLDENBERG, M. M. Medical management of Parkinson’s disease. Pharmacy and Therapeutics, v. 33, n. 10, p. 590–594, 599–606, 2008.
GONÇALVES I. G.; SOUZA M. C. A. de. Abordagem geral da doença de Parkinson. Revista Eletrônica Acervo Científico, v. 44, e12557, 2023.
GURURAJAN A.; TAYLOR D. A.; MALONE D. T. Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia. Behavioural Brain Research, v. 22, n. 2, p. 299-308, 2011.
HAFIDA, E. G.; RACHID, S.; HALIMA, G.; NAJIB, K. CBD's potential impact on Parkinson's disease: an updated overview. Open Medicine (Warsaw), v. 19, n. 1, art. 20241075, 2024.
HAZEKAMP A. The Trouble with CBD Oil. Medical Cannabis and Cannabinoids, v. 1, p. 65-72, 2018.
IFFLAND, K.; GROTENHERMEN, F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis and Cannabinoid Research, v. 2, n. 1, p. 139-154, 2017.
KOLB B.; SABER H.; FADEL H.; RAJAH G. The endocannabinoid system and stroke: A focused review. Brain Circulation, v. 5, p. 1-7, 2019.
KOULI, A.; TORSNEY, K. M.; KUAN, W.-L. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. In: STOKER, T. B.; GREENLAND, J. C. (ed.). Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane: Codon Publications, 2018. Cap. 1. Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK536722/. Acesso em 03 de maio de 2025.
LATTANZI S.; TRINKA E.; STRIANO P.; ROCCHI C.; SALVEMINI S.; SILVESTRINI M.; BRIGO F. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome. CNS Drugs, v. 35, p. 265-281, 2021.
LIGRESTI A.; MORIELLO AS; STAROWICZ K; MATIAS I; PISANTI S; De PETROCELLIS L; LAEZZA C; PORTELLA G; BIFULCO M; Di MARZO V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. v. 318, n. 3, p. 1375-1387, 2006.
LIM, K.; SEE, Y. M.; LEE, J. A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders. Clinical Psychopharmacology and Neuroscience, v. 15, n. 4, p. 301–312, 2017.
MCGUIRE P.; ROBSON P.; CUBALA W. J.; VASILE D.; MORRISON P. D.; BARRON R.; TAYLOR A.; WRIGHT S. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. American Journal of Psychiatry, v. 175, n. 3, p. 225-231, 2018.
MLOST J.; WASIK A.; STAROWICZ K. Role of endocannabinoid system in dopamine signalling within the reward circuits affected by chronic pain. Pharmacological Research, v. 143, p. 40-47, 2019.
MORASH, M. G.; NIXON, J.; SHIMODA, L. M. N.; TURNER, H.; STOKES, A. J.; SMALL-HOWARD, A. L.; ELLIS, L. D. Identification of minimum essential therapeutic mixtures from cannabis plant extracts by screening in cell and animal models of Parkinson's disease. Frontiers in Pharmacology, v. 13, p. 907579, 2022.
PALMIERI B.; LAURINO C.; VADALÀ M. A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. Clinica Terapeutica, v. 170, n. 2, p. 93-99, 2019.
PEREZ, Matheus. Papel neuroprotetor do canabidiol em ratos neonatos após transecção do nervo isquiático. 2013. 86 f. Dissertação (Mestrado em Biologia Celular e Estrutural) – Universidade Estadual de Campinas, Instituto de Biologia, Campinas, 2013. Disponível em: https://hdl.handle.net/20.500.12733/1619982. Acesso em: 10 mai. 2025.
PINTORI, N.; CARIA, F.; DE LUCA, M. A.; MILIANO, C. THC and CBD: villain versus hero? Insights into adolescent exposure. International Journal of Molecular Sciences, Basel, v. 24, n. 6, p. 5251, 2023.
POLITIS M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nature Reviews Neurology, v. 10, n. 12, p. 708–722, 2014.
SAWADA, H.; OEDA, T.; KUNO, S.; NOMOTO, M.; YAMAMOTO, K.; YAMAMOTO, M.; HISANAGA, K.; KAWAMURA, T.; AMANTADINE STUDY GROUP. Amantadine for Dyskinesias in Parkinson’s Disease: A Randomized Controlled Trial. PLOS ONE, v. 5, n. 12, art. e15298, 2010.
SINGH, K.; BHUSHAN, B.; CHANCHAL, D. K.; SHARMA, S. K.; RANI, K.; YADAV, M. K.; PORWAL, P.; KUMAR, S.; SHARMA, A.; VIRMANI, T.; KUMAR, G.; NOMAN, A. A. Emerging therapeutic potential of cannabidiol (CBD) in neurological disorders: a comprehensive review. Behavioral Neurology, v. 2023, p. 1–16, 2023.
SOUZA, C. F. M.; ALMEIDA, H. C. P.; SOUSA, J. B.; COSTA, P. H.; SILVEIRA, Y. S. S.; BEZERRA, J. C. L. A Doença de Parkinson e o Processo de Envelhecimento Motor: Uma Revisão de Literatura. Revista Neurociências, São Paulo, v. 19, n. 4, p. 718–723, 2011.
SOUZA J. D. R.; PACHECO J. C.; ROSSI G. N.; de-PAULO B. O.; ZUARDI A. W.; GUIMARÃES F. S.; HALLAK J. E. C.; CRIPPA J. A.; DOS SANTOS R. G. Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022). Pharmaceutics, v.14, n. 12, art. 2598, 2022.
TOLOSA, E.; GARRIDO, A.; SCHOLZ, S. W.; POEWE, W. Challenges in the diagnosis of Parkinson's disease. The Lancet Neurology, v. 20, n. 5, p. 385-397, 2021.
WATERS C.H.; SETHI K. D.; HAUSER R. A.; MOLHO E.; BERTONI J. M.; ZYDIS SELEGILINE STUDY GROUP. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Movement Disorders, v. 19, n. 4, p. 426-432, 2004.
WERNECK, A. L. S. Doença de Parkinson: etiopatogenia, clínica e terapêutica. Revista Hospital Universitário Pedro Ernesto, Rio de Janeiro, v. 9, n. 1, p. 10–19, 2010.
ZAHOOR I.; SHAFI, A.; HAQ, E. Pharmacological Treatment of Parkinson’s Disease. In: STOKER, T. B.; GREENLAND, J. C. (ed.). Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane: Codon Publications, 2018. Cap. 7. Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK536726/. Acesso em: 04 maio 2025.
ZHAO, Y.; ZHANG, Z.; QIN, S.; FAN, W.; LI, W.; LIU, J.; WANG, S.; XU, Z.; ZHAO, M. Acupuncture for Parkinson’s Disease: Efficacy Evaluation and Mechanisms in the Dopaminergic Neural Circuit. Neural Plasticity, v. 2021, art. 9926445, 2021.
ZUARDI, A. W.; CRIPPA, J. A. S.; HALLAK, J. E. C.; PINTO, J. P.; CHAGAS, M. H. N.; RODRIGUES, G. G. R.; DURSUN, S. M.; TUMAS, V. Cannabidiol for the treatment of psychosis in Parkinson's disease. Journal of Psychopharmacology, v. 23, n. 8, p. 979–983, 2009.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Bianca Milhoretto Pampuch, Paulo Cézar Gregório, Caroline Cardozo Gasparin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
